Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversibly binding P2Y12 platelet inhibitor. It prevents adenosine triphosphate (ATP) from binding to the P2Y12 receptor on platelets.
## Primary Indications
* **Acute Coronary Syndromes (ACS):** In combination with aspirin, for the reduction of thrombotic cardiovascular events (e.g., cardiovascular death, myocardial infarction, stroke) in patients with ACS.
* **Myocardial Infarction (MI):** In patients with a history of MI, in combination with aspirin, to reduce the rate of cardiovascular death, myocardial infarction, and stroke.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for at least 12 months, or longer if tolerated and indicated.
* **History of MI (≥1 year post-ACS or MI):**
* **Maintenance Dose:** 60 mg orally twice daily.
## Pediatric Dosing
* Ticagrelor is **not recommended** for use in pediatric patients. Safety and efficacy have not been established.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment necessary.
* **Hepatic Impairment:**
* **Mild to Moderate:** No dose adjustment necessary.
* **Severe:** Use with caution; data is limited.
## Contraindications
* Active pathological bleeding (e.g., intracranial hemorrhage, gastrointestinal bleeding).
* History of transient ischemic attack (TIA) or stroke (for the 60 mg twice daily indication).
* Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, nefazodone).
* Known hypersensitivity to ticagrelor or any of its excipients.
## Adverse Effects
* **Most Common:** Bleeding (including life-threatening and fatal), dyspnea, ventricular pauses, bradycardia.
* **Other:** Hypotension, atrial fibrillation, cough, abdominal pain, diarrhea, rash.
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Avoid co-administration with strong CYP3A4 substrates with narrow therapeutic indices (e.g., simvastatin, lovastatin).
* **CYP3A4 Inducers:** Increased ticagrelor clearance and reduced efficacy.
* **Aspirin:** Concurrent use increases bleeding risk.
* **Other Anticoagulants/Antiplatelets:** Increased bleeding risk.
* **Dose of Aspirin:** A maintenance dose of aspirin >100 mg may increase the risk of bleeding. The optimal duration of dual antiplatelet therapy (DAPT) should be individualized.
## Monitoring
* **Bleeding:** Closely monitor for signs and symptoms of bleeding.
* **Cardiac Function:** Monitor for bradycardia, especially in patients with pre-existing risk factors.
## Clinical Pearls
* Ticagrelor is a P2Y12 inhibitor with a rapid onset and offset of action due to its reversible binding.
* The 180 mg loading dose is crucial for immediate platelet inhibition in ACS.
* Dyspnea is a common side effect and can be transient or persistent. It does not necessarily indicate cardiac issues but warrants evaluation.
* Discontinuation of ticagrelor should be avoided if possible, as it increases the risk of thrombotic events. If interruption is necessary, resume as soon as possible.
* Patients with a history of stroke or TIA should generally not receive ticagrelor 60 mg twice daily.
***
*Please verify current prescribing information for the most up-to-date details.*
